ZURICH (Reuters) - Swiss drugmaker Roche's hopes of having the first immunotherapy cocktail to be approved as an initial treatment for an aggressive form of lung cancer remained intact on Monday after a trial showed positive survival data.
Original Article: Study preserves hopes for Roche's Tecentriq in lung cancer